75 results
8-K
EX-99.1
BMY
Bristol-Myers Squibb Co.
8 Jan 24
Regulation FD Disclosure
10:29am
USE
Reblozyl: Significant growth opportunities in MDS-associated anemia and beyond Ongoing registrational studies 1L TD myelofibrosis(INDEPENDENCE
8-K
EX-1.1
BMY
Bristol-Myers Squibb Co.
13 Nov 23
Other Events
4:19pm
Investments, Inc.
PNC Capital Markets LLC
CAVU Securities, LLC
Drexel Hamilton, LLC
Independence Point Securities LLC
*We expect that delivery … Hamilton, LLC
Independence Point Securities LLC
Total
II-2
SCHEDULE III
Schedule III(a) Issuer Free Writing Prospectuses not included in the Pricing
424B5
u4agjfcmrea2z8znb9z
1 Nov 23
Prospectus supplement for primary offering
4:16pm
FWP
dsndjb9
30 Oct 23
Free writing prospectus
5:26pm
8-K
EX-99.2
59m2mdrl4iww
26 Oct 23
Bristol Myers Squibb Reports Third Quarter Financial Results for 2023
7:44am
8-K
EX-99.2
xgfsc
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
EX-99.1
sxjmmcm4or8 77b14x
27 Jul 23
Bristol Myers Squibb Reports Second Quarter Financial Results for 2023
7:50am
8-K
emnam fq6vy0l9b
4 May 23
Departure of Directors or Certain Officers
4:48pm
8-K
EX-99.2
hd60y
27 Apr 23
Bristol Myers Squibb Reports First Quarter Financial Results for 2023
7:45am
DEFA14A
l7e5jy nk
10 Apr 23
Additional proxy soliciting materials
5:12pm
8-K
EX-99.3
die4ln63w yvh94
26 Oct 22
Bristol Myers Squibb Reports Third Quarter Financial Results for 2022
7:48am
8-K
EX-99.3
p5u34mjdgjs
27 Jul 22
Bristol Myers Squibb Reports Second Quarter Financial Results for 2022
7:44am
8-K
2dqasbib4xp5 il58
15 Jun 22
Departure of Directors or Certain Officers
4:29pm
8-K
EX-99.3
6cn93l01lsx 2e9rs1a0
29 Apr 22
Bristol Myers Squibb Reports First Quarter Financial Results for 2022
7:42am
DEFA14A
9ndalh7n2tkwv9p7x
20 Apr 22
Additional proxy soliciting materials
4:30pm
PX14A6G
2dsofqjoa6uxlag9q5
5 Apr 22
Letter to shareholders
4:53pm